SEARCH:   Advanced

Blood, 1 September 2006, Vol. 108, No. 5, pp. 1504-1508. Prepublished online as a Blood First Edition Paper on May 11, 2006; DOI 10.1182/blood-2006-01-013367. This Article Full Text (PDF) All Versions of this Article: blood-2006-01-013367v1 108/5/1504    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Buske, C. Articles by Hiddemann, W. Search for Related Content PubMed PubMed Citation Articles by Buske, C. Articles by Hiddemann, W. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 17, 2006 Accepted April 19, 2006 The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with Rituximab and the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) with respect to treatment outcome Christian Buske*, Eva Hoster, Martin Dreyling, Joerg Hasford, Michael Unterhalt, and Wolfgang Hiddemann Department of Internal Medicine III, Klinikum GroBhadern, University of Munich Institute of Medical Informatics, Biometry and Epidemiology, University of Munich * Corresponding author; email: buske{at}gsf.de. The Follicular Lymphoma International Prognostic Index (FLIPI) was developed to predict prognosis of patients with follicular lymphoma (FL). However, it was based on different protocols, none of which included Rituximab. The current analysis aimed at evaluating the predictive value of the FLIPI for treatment outcome in 362 patients with advanced stage FL treated front-line with Rituximab/CHOP in a prospective trial of the German Low Grade Lymphoma Study Group. According to the FLIPI, 14% of the patients were classified as low risk, 41% as intermediate risk and 45% as high risk patients. With a 2-year time to treatment failure (TTF) of 67%, high risk patients had a significantly shorter TTF as compared to low or intermediate risk patients (2-year TTF of 92% and 90%, respectively; p = 0.0002). Our data demonstrate that the FLIPI is able to identify high risk patients with advanced stage FL after first-line treatment with Rituximab/chemotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. de Vos, A. Goy, S. R. Dakhil, M. N. Saleh, P. McLaughlin, R. Belt, C. R. Flowers, M. Knapp, L. Hart, D. Patel-Donnelly, et al. Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma J. Clin. Oncol., October 20, 2009; 27(30): 5023 - 5030. [Abstract] [Full Text] [PDF] S. A. M. van de Schans, E. W. Steyerberg, M. R. Nijziel, G.-J. Creemers, M. L. Janssen-Heijnen, and D. J. van Spronsen Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting Ann. Onc., October 1, 2009; 20(10): 1697 - 1702. [Abstract] [Full Text] [PDF] F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence Oncologist, October 1, 2009; 14(suppl_2): 17 - 29. [Abstract] [Full Text] [PDF] M. Federico, M. Bellei, L. Marcheselli, S. Luminari, A. Lopez-Guillermo, U. Vitolo, B. Pro, S. Pileri, A. Pulsoni, P. Soubeyran, et al. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project J. Clin. Oncol., September 20, 2009; 27(27): 4555 - 4562. [Abstract] [Full Text] [PDF] M. Dreyling and On behalf of the ESMO Guidelines Working Group Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv119 - iv120. [Full Text] [PDF] M. Kornacker, J. Stumm, C. Pott, S. Dietrich, S. Sussmilch, M. Hensel, M. Nickelsen, M. Witzens-Harig, M. Kneba, N. Schmitz, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up Ann. Onc., April 1, 2009; 20(4): 722 - 728. [Abstract] [Full Text] [PDF] J. W. Friedberg, M. D. Taylor, J. R. Cerhan, C. R. Flowers, H. Dillon, C. M. Farber, E. S. Rogers, J. D. Hainsworth, E. K. Wong, J. M. Vose, et al. Follicular Lymphoma in the United States: First Report of the National LymphoCare Study J. Clin. Oncol., March 10, 2009; 27(8): 1202 - 1208. [Abstract] [Full Text] [PDF] P. McLaughlin, S. Neelapu, M. Fanale, M. Rodriguez, A. Ayala, B. Pro, F.B. Hagemeister, A. Younes, S. Neel, N. Fowler, et al. R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 3056 - 3056. [Abstract] D. O'Shea, C. O'Riain, C. Taylor, R. Waters, E. Carlotti, F. MacDougall, J. Gribben, A. Rosenwald, G. Ott, L. M. Rimsza, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival Blood, October 15, 2008; 112(8): 3126 - 3129. [Abstract] [Full Text] [PDF] R. Marcus, K. Imrie, P. Solal-Celigny, J. V. Catalano, A. Dmoszynska, J. C. Raposo, F. C. Offner, J. Gomez-Codina, A. Belch, D. Cunningham, et al. Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma J. Clin. Oncol., October 1, 2008; 26(28): 4579 - 4586. [Abstract] [Full Text] [PDF] M. Bendandi Aiming at a Curative Strategy for Follicular Lymphoma CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317. [Abstract] [Full Text] [PDF] M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP Blood, May 1, 2008; 111(9): 4664 - 4667. [Abstract] [Full Text] [PDF] M. J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego, A. Younes, J. E. Romaguera, F. B. Hagemeister, L. Kwak, et al. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma Ann. Onc., March 1, 2008; 19(3): 553 - 559. [Abstract] [Full Text] [PDF] M. Federico, C. Guglielmi, S. Luminari, C. Mammi, L. Marcheselli, U. Gianelli, A. Maiorana, F. Merli, M. Bellei, S. Pozzi, et al. Prognostic relevance of serum {beta}2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study Haematologica, November 1, 2007; 92(11): 1482 - 1488. [Abstract] [Full Text] [PDF] M. Taskinen, M.-L. Karjalainen-Lindsberg, H. Nyman, L.-M. Eerola, and S. Leppa A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone Clin. Cancer Res., October 1, 2007; 13(19): 5784 - 5789. [Abstract] [Full Text] [PDF] W. Klapper, E. Hoster, L. Rolver, C. Schrader, D. Janssen, M. Tiemann, H.-W. Bernd, O. Determann, M.-L. Hansmann, P. Moller, et al. Tumor Sclerosis but Not Cell Proliferation or Malignancy Grade Is a Prognostic Marker in Advanced-Stage Follicular Lymphoma: The German Low Grade Lymphoma Study Group J. Clin. Oncol., August 1, 2007; 25(22): 3330 - 3336. [Abstract] [Full Text] [PDF] B. E. Wahlin, B. Sander, B. Christensson, and E. Kimby CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma Clin. Cancer Res., January 15, 2007; 13(2): 388 - 397. [Abstract] [Full Text] [PDF] C Nickenig, M Dreyling, E Hoster, W-D Ludwig, B Dorken, M Freund, C Huber, A Ganser, L Trumper, R Forstpointner, et al. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group Ann. Onc., January 1, 2007; 18(1): 136 - 142. [Abstract] [Full Text] [PDF] G. A. Salles Clinical Features, Prognosis and Treatment of Follicular Lymphoma Hematology, January 1, 2007; 2007(1): 216 - 225. [Abstract] [Full Text] [PDF] K. van Besien Autologous transplantation for follicular lymphoma? Not too soon! Blood, October 15, 2006; 108(8): 2496 - 2497. [Full Text] [PDF] L. H. Sehn Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 295 - 302. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020